Skip to content

EXtending the tIme Window of Thrombolysis by ButyphThalide up to 6 Hours After Onset (EXIT-BT)

EXtending the tIme Window of Thrombolysis by ButyphThalide up to 6 Hours After Onset (EXIT-BT): a Prospective, Randomized, Blinded Assessment of Outcome and Open Label Multi-center Study

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05189509
Enrollment
100
Registered
2022-01-12
Start date
2022-02-11
Completion date
2022-12-28
Last updated
2023-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke, Ischemic

Brief summary

To date, the time window of intravenous thrombolysis is limited within 4.5 hours of stroke onset. Although EXTEND study has proved that intravenous thrombolysis can be extended from 4.5 to 9 hours, but the eligible patients must be selected by CTP. Thus, it is of clinical importance how to extend the time window of intravenous thrombolysis, which can benifit more patients. The current trial aims to investigate the effect of intravenous thrombolysis with TNK from 4.5 to 6 hours in ischemic stroke with help of Butyphthalide, which was found to be neuroprotective.

Interventions

DRUGTNK-Tissue Plasminogen Activator

0.25 mg TNK thrombolysis

Sponsors

General Hospital of Shenyang Military Region
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* age: 18-80; * ischemic stroke confirmed by brain CT or MRI * the time from onset to treatment: 4.5-6 hours * NIHSS≥4 * prestroke mRS≤1 * signed informed consent

Exclusion criteria

* prestroke mRS≥2 * planned endovascular treatment * planned intravenous thrombolysis based on WAKE-UP or EXTEND study criterion * any contraindiction of intravenous thrombolysis * other unsuitable conditions judged by investigator

Design outcomes

Primary

MeasureTime frameDescription
symptomatic intracerebral hemorrhage36 hoursany evidence of bleeding on the head CT scan associated with clinically significant neurological deterioration (NIHSS score ≥4 points increase)

Secondary

MeasureTime frameDescription
The proportion of favourable prognosis (mRS 0-2)Day 90the minimum and maximum values of modified Rankin Score are 0 and 6, respectively; higher score mean a worse outcome
Distribution of modified Rankin ScoreDay 90the minimum and maximum values of modified Rankin Score are 0 and 6, respectively; higher score mean a worse outcome
Changes in National Institute of Health stroke scale (NIHSS)24 hours, 2 weeksthe minimum and maximum values of NIHSS are 0 and 42, respectively; higher NIHSS mean a worse outcome
The proportion of excellent prognosis (mRS 0-1)Day 90the minimum and maximum values of modified Rankin Score are 0 and 6, respectively; higher score mean a worse outcome
any cerebral microbleeding(CMB)48 hoursCMB is measured by SWI sequence
infarct volume48 hoursinfarct volume is measured by DWI sequence
proportion of deathDay 90death due to any cause
any intracerebral hemorrhage36 hoursthe evidence of bleeding on the head CT scan

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026